Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation

Journal of Urology

Volumn 158, Issue 1, 1997, Pages 212-216

  Cardillo, Marina ^b   Berchem, Guy ^b   Tarkington, Mary Anne ^b   Krajewski, Stanislaw ^b   Krajewski, Maryla ^b   Reed, John C ^b   Tehan, Timothy ^b   Ortega, Louis ^b   Lage, Janice ^b   Gelmann, Edward P ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Apoptosis; bcl 2; Benign prostatic hyperplasia; GnRH agonist

Indexed keywords

GOSERELIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROSTATECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030914631     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199707000-00073     Document Type: Article

References (41)

1. Guess, H. A.: Epidemiology and natural history of benign prostatic hyperplasia. Urol. Clin. North Am., 22: 247, 1995.
2. Holtgrewe, H. L., Mebust, W. K. and Dowd, J. B.: Transurethral prostatectomy: Practice aspects of the dominant operation in American urology. J. Urol., 141: 248, 1989.
3. Devonec, M., Berger, N. and Perrin, P.: Transurethral microwave heating of the prostate - or from hyperthermia to thermotherapy. J. Endourol., 5: 129, 1991.
4. Goldfarb, B., Bartkiw, T. and Trachtenberg, J.: Microwave therapy of benign prostatic hyperplasia. Urol. Clin. North Am., 22: 431, 1995.
5. Lepor, H., Knopp-Maloney, G. and Sunshine, H.: A dose titration study evaluating terazosin a selective one-a-day alphal blocker for the treatment of symptomatic benign prostatic hyperplasia. J. Urol., 143: 1393, 1990.
6. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R. and Tenover, J. S.: The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med., 327: 1185, 1992.
7. Kyprianou, N. and Isaacs, J. T.: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122: 552, 1988.
8. Kerr, J. F. R. and Searle, J.: Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch (B)., 13: 87, 1977.
9. Imperato-McGinley, J., Guerrero, L., Gautier, T. and Peterson, R. E.: Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science, 186: 1213, 1974.
10. Walsh, P. C., Madden, J. D., Harrod, M. J., Goldstein, J. L., MacDonald, P. C. and Wilson, J. D.: Familial incomplete male pseudohermaphroditism, type 2: decreased hihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. New Engl. J. Med., 291: 944, 1974.
11. Huggins, C. and Hodges, C. V.: Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293, 1941.
12. Huggins, C., Stevens, R. E. and Hodges, C. L.: Studies on prostatic cancer. II. The effect of castration on clinical patients with carcinoma of the prostate. Arch. Surg., 43: 209, 1941.
13. Crawford, E. D., Eisenberger, M., McCleod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A. and Goodman, P. J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med., 321: 419, 1989.
14. Westin, P., Stattin, P., Damber, J.-E. and Bergh, A.: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol., 146: 1368, 1995.
15. Partin, A. W., Oesterling, J. E., Epstein, J. I., Horton, R. and Walsh, P. C.: Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J. Urol., 145: 405, 1991.
16. Berry, S. J., Coffey, D. S. and Walsh, P. C.: The development of human benign prostatic hyperplasia with age. J. Urol., 132: 474, 1984.
17. Huggins, C. and Stevens, R. A.: The effect of castration in benign hypertrophy of the prostate in man. J. Urol., 43: 705, 1940.
18. Eri, L. M. and Tveter, K. J.: A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J. Urol., 150: 90, 1993.
19. Eri, L. M. and Tveter, K. J.: A prospective, placebo-controlled study of luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J. Urol., 150: 359, 1993.
20. Gabrilove, J. L., Levine, A. C., Kirschenbaum, A. and Droller, M.: Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J. Clin. Endocrinol. Metab., 69: 629, 1989.
21. The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N. Engl. J. Med., 311: 1281, 1984.
22. Taniguchi, J., Moriyama, S., Kurimoto, S., Kameyama, S. and Kawabe, K.: Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of bcl-2 oncoprotein in human prostatic cancer. Br. J. Urol., 77: 719, 1996.
23. Krajewski, S., Krajewska, M., Shabaik, A., Wang, H. G., Irie, S., Fong, L. and Reed, J. C.: Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res., 54: 5501, 1994.
24. Krajewski, S., Blomqvist, C., Franssila, K., Krajewski, M., Wasenius, W.-M., Niskanen, E., Nording, S. and Reed, J. C.: Reduced expression of proapoptotic gene BAX is associated with poor response to combination chemotherapy and shorter survival in women with metastatic breast cancer. Cancer Res., 55: 4471, 1995.
25. Krajewski, S., Krajewski, M. and Reed, J. C.: Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res., 56: 2849, 1996.
26. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J.-T., Tu, S.-M. and Campbell, M. L.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940, 1992.
27. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Korsmeyer, S. and Buttyan, R.: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol., 143: 390, 1993.
28. Oltvai, Z., Milliman, C. and Korsmeyer, S. J.: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609, 1993.
29. Reed, J. C.: Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1, 1994.
30. Sato, T., Kanada, M., Bodrug, S., Irie, S., Iwama, N., Boise, L., Thompson, C., Fong, L., Wang, H.-G. and Reed, J. C.: Investigations of bcl-2 protein family interactions using yeast two-hybrid system. Proc. Natl. Acad. Sci. USA, 91: 9238, 1994.
31. Boise L. H., Gonzaalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nune, G. and Thompson, C.: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597, 1993.
32. Chittenden, T., Harrington, E. A., O'Connor, R., Flemington, C., Lutz, R. J., Evan, G. I. and Guild, B. C.: Induction of apoptosis by the bcl-2 homologue Bak. Nature, 374: 733, 1995.
33. Kiefer, M. C., Brauer, M. J., Powers, V. C., Wu, J. J., Ubansky, S. R., Tomei, L. D. and Barr, P. J.: Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak, Nature, 374: 736, 1995.
34. Krajewski, S., Krajewska, M., Shabaik, A., Miyashita, T., Wang, H. G. and Reed, J. C.: Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am. J. Pathol., 145: 1323, 1994.
35. Yokoyama, M., Seki, N., Tamai, M. and Takeuchi, M.: Benign prostatic hyperplasia in a patient castrated in his youth. J. Urol., 142: 134, 1989.
36. Scott, W. W.: What makes the prostate grow? J. Urol., 70: 477, 1953.
37. Coffey, D. S. and Walsh, P. C.: Clinical and experimental studies of benign prostatic hyperplasia. Urol. Clin. North Am., 17: 573, 1990.
38. Walensky, L. D., Coffey, D. S., Chen, T. H., Wu, T. C. and Pasternack, G. R.: A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res., 53: 4720, 1993.
39. Berchem, G. J., Bosseler, M., Sugars, L. Y., Voeller, H. J., Zeitlin, S. and Gelmann, E. P.: Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55: 735, 1995.
40. Raffo, A. J., Perlman, H., Chen, M. W., Day, M. L., Streitman, J. S. and Buttyan, R.: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438, 1995.
41. Shabaik, A. S., Krajewski, S., Burgan, A., Krajewski, M. and Reed, J. C.: bcl-2 protooncogene expression in normal, hyperplastic and neoplastic prostate tissue. J. Urol. Pathol., 3: 17, 1995.